PositiveID, in conjunction with development partner Receptors LLC (Receptors), is also developing an in vivo glucose-sensing RFID microchip to detect glucose levels in the human body. PositiveID and Receptors are currently in Phase II development, the goal of which is to develop a proof-of-principal sensing system consisting of a Combinatorial Artificial Receptors Array (CARA?„?) modified support and its complementary fluorophore labeled synthetic competitor agent. The companies expect that this sensing system will demonstrate a glucose concentration response in model blood and interstitial fluid matrices. Phase II is expected to be completed by mid-2010 and will build on Phase I, which successfully demonstrated the application of the glucose-sensing system to the detection of glucose levels.

Scott R. Silverman, Chairman and CEO of PositiveID, stated, As we continue the development of our glucose-sensing microchip with Receptors, we believe the acquisition of the intellectual property and assets of Easy Check Medical Diagnostics, LLC provides complementary, non-invasive testing products and wireless communication tools that can position us as a significant player in diabetes management. Existing solutions in diabetes care are painful and have mediocre compliance rates. With our current portfolio of products under development, we are hopeful we can improve diabetics ™ lives while helping them manage their healthy glucose levels, thereby decreasing the risk of diabetes-related complications and reducing medical costs.

According to a November 2009 study by researchers at the University of Chicago published in the journal Diabetes Care, the number of diabetics in the U.S., which currently stands at 23.7 million, may almost double in 25 years, and the annual cost of treating them may triple to $336 billion.

SOURCE PositiveID Corporation